ITUS (ITUS) Earns Media Sentiment Rating of -0.04

Headlines about ITUS (NASDAQ:ITUS) have trended somewhat negative on Saturday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ITUS earned a daily sentiment score of -0.04 on Accern’s scale. Accern also assigned headlines about the business services provider an impact score of 47.3558704916007 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, ValuEngine lowered ITUS from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th.

Shares of ITUS (NASDAQ:ITUS) opened at $2.36 on Friday. ITUS has a 52 week low of $0.60 and a 52 week high of $5.50. The firm has a market capitalization of $40.57, a PE ratio of -3.75 and a beta of -1.20.

COPYRIGHT VIOLATION NOTICE: “ITUS (ITUS) Earns Media Sentiment Rating of -0.04” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://weekherald.com/2017/12/30/itus-itus-earns-media-sentiment-rating-of-0-04.html.

About ITUS

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream.

Insider Buying and Selling by Quarter for ITUS (NASDAQ:ITUS)

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply